2019
Treatment of drug-resistant epilepsy in patients with periventricular nodular heterotopia using RNS® System: Efficacy and description of chronic electrophysiological recordings
Nune G, Arcot Desai S, Razavi B, Agostini MA, Bergey GK, Herekar AA, Hirsch LJ, Lee RW, Rutecki PA, Srinivasan S, Van Ness PC, Tcheng TK, Morrell MJ. Treatment of drug-resistant epilepsy in patients with periventricular nodular heterotopia using RNS® System: Efficacy and description of chronic electrophysiological recordings. Clinical Neurophysiology 2019, 130: 1196-1207. PMID: 31163364, DOI: 10.1016/j.clinph.2019.04.706.Peer-Reviewed Original ResearchConceptsPeriventricular nodular heterotopiaClinical seizure frequencySeizure frequencySeizure rateNodular heterotopiaDirect brain-responsive neurostimulationBrain-responsive neurostimulationDrug-resistant epilepsyEffective treatment optionSeizure-onset patternsSeizure propagation patternsChronic electrophysiological recordingsSeizure reductionClinical seizuresSuch patientsElectrographic seizuresPattern of spreadIntractable seizuresTreatment optionsEpileptogenic networksSeizure generationOnset typeMean reductionLead locationPatients
2013
High-dose midazolam infusion for refractory status epilepticus
Fernandez A, Lantigua H, Lesch C, Shao B, Foreman B, Schmidt JM, Hirsch LJ, Mayer SA, Claassen J. High-dose midazolam infusion for refractory status epilepticus. Neurology 2013, 82: 359-365. PMID: 24363133, PMCID: PMC3929199, DOI: 10.1212/wnl.0000000000000054.Peer-Reviewed Original ResearchConceptsHigh-dose groupRefractory status epilepticusLow-dose groupStatus epilepticusLower mortalityHigh-dose midazolam infusionLower seizure ratesStatus epilepticus onsetClass III evidenceLow-dose protocolHigher infusion ratesHospital complicationsHospital courseSeizure recurrenceBaseline characteristicsSeizure controlWithdrawal seizuresMedian timeDischarge mortalityMidazolam dosesMidazolam infusionSeizure rateWorse outcomesTreatment protocolInfusion rate